Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Century Therapeutics (IPSC) Change in Accured Expenses (2022 - 2025)

Century Therapeutics (IPSC) has disclosed Change in Accured Expenses for 4 consecutive years, with $1.1 million as the latest value for Q4 2025.

  • Quarterly Change in Accured Expenses fell 62.87% to $1.1 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$4.3 million through Dec 2025, down 369.35% year-over-year, with the annual reading at -$4.3 million for FY2025, 369.35% down from the prior year.
  • Change in Accured Expenses for Q4 2025 was $1.1 million at Century Therapeutics, up from $443000.0 in the prior quarter.
  • The five-year high for Change in Accured Expenses was $2.9 million in Q3 2023, with the low at -$6.5 million in Q1 2025.
  • Average Change in Accured Expenses over 4 years is $32125.0, with a median of $893000.0 recorded in 2025.
  • The sharpest move saw Change in Accured Expenses tumbled 310.87% in 2023, then soared 397.06% in 2025.
  • Over 4 years, Change in Accured Expenses stood at $1.1 million in 2022, then crashed by 310.87% to -$2.4 million in 2023, then skyrocketed by 221.74% to $2.9 million in 2024, then plummeted by 62.87% to $1.1 million in 2025.
  • According to Business Quant data, Change in Accured Expenses over the past three periods came in at $1.1 million, $443000.0, and $707000.0 for Q4 2025, Q3 2025, and Q2 2025 respectively.